RDHL (RedHill Biopharma Ltd) Earnings per share for the last four quarters

Public company logo of RedHill Biopharma Ltd (RDHL)

The annual percentage change in EPS TTM on the GURU.Markets portal demonstrates current trends, where the level of 94.30 represents the current value. RedHill Biopharma (RDHL) has outsourced logistics and trials to external contractors, creating a strong operational dependency. The company generates revenue from the sale of proprietary Crohn's disease treatments through insurance programs, expanding its US distribution as gastroenterologists increasingly recognize the efficacy of the drugs.

RedHill - RDHL Net earnings per share (EPS TTM) (period 02/11/2024 - 11/18/2026)

RedHill Biopharma Ltd. - analytical breakdowns and key metrics (RDHL)

- market price and analyst price targets:
Fundamental company valuation:RDHL (RedHill)
Finished products of redhillbio.com

RedHill Biopharma (RDHL) utilizes production outsourcing and fixed R&D costs to create powerful operating leverage for scaling profits. This indicator measures the percentage change in earnings per share over the last 12 months relative to the same period last year. This metric reflects the speed of business capitalization and the efficiency of cost management. The indicator's dynamics allow for the identification of overpayment risks if momentum fades. By analyzing the YoY growth in net income per share over the last 12 months, an investor assesses market value through the lens of discounted future cash flows.